HONG KONG, June 4, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the National Medical Products Administration (NMPA) has approved the company's first- in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, for the first-line treatment of...
Hence then, the article about akeso s pd 1 ctla 4 bispecific antibody cadonilimab approved for first line treatment of cervical cancer in all comer populations third approved indication for cadonilimab was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso's PD-1/CTLA-4 Bispecific Antibody Cadonilimab Approved for First-Line Treatment of Cervical Cancer in All-Comer Populations--Third Approved Indication for Cadonilimab )
Also on site :
- Teens arrested after large disturbance, multiple fights at Joliet mall
- Transcript: Bank of America CEO Brian Moynihan on "Face the Nation with Margaret Brennan," Dec. 28, 2025
- Feel Free customers say the kratom drink is making them sick. Toothless FDA rules on dietary supplements are helping it remain a bestseller